Literature DB >> 24154729

Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis.

Marco P Donadini1, Walter Ageno, Emilia Antonucci, Benilde Cosmi, Michael J Kovacs, Grégoire Le Gal, Paul Ockelford, Daniela Poli, Paolo Prandoni, Marc Rodger, Giorgia Saccullo, Sergio Siragusa, Laura Young, Matteo Bonzini, Monica Caprioli, Francesco Dentali, Alfonso Iorio, James D Douketis.   

Abstract

Residual venous obstruction (RVO) could improve the stratification of the risk of recurrence after unprovoked deep vein thrombosis (DVT), but results from clinical studies and study-level meta-analyses are conflicting. It was the objective of this analysis to determine if RVO is a valid predictor of recurrent venous thromboembolism (VTE) in patients with a first unprovoked DVT who had received at least three months of anticoagulant therapy. Individual patient data were obtained from the datasets of original studies, after a systematic search of electronic databases (Medline, Embase, Cochrane Library), supplemented by manual reviewing of the reference lists and contacting content experts. A multivariate, shared-frailty Cox model was used to calculate hazard ratios (HRs) for recurrent VTE, including, as covariates: RVO; age; sex; anticoagulation duration before RVO assessment; and anticoagulation continuation after RVO assessment. A total of 2,527 patients from 10 prospective studies were included. RVO was found in 1,380 patients (55.1%) after a median of six months from a first unprovoked DVT. Recurrent VTE occurred in 399 patients (15.8%) during a median follow-up of 23.3 months. After multivariate Cox analysis, RVO was independently associated with recurrent VTE (HR = 1.32, 95% confidence interval [CI]: 1.06-1.65). The association was stronger if RVO was detected early, i.e. at three months after DVT (HR = 2.17; 95% CI: 1.11-4.25), but non-significant if detected later, i.e. >6 months (HR = 1.19; 95% CI: 0.87-1.61). In conclusion, after a first unprovoked DVT, RVO is a weak overall predictor of recurrent VTE. The association is stronger if RVO is detected at an earlier time (3 months) after thrombosis.

Entities:  

Keywords:  Residual venous obstruction; patient-level meta-analysis; recurrent venous thromboembolism; unprovoked deep vein thrombosis

Mesh:

Substances:

Year:  2013        PMID: 24154729     DOI: 10.1160/TH13-04-0336

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  21 in total

Review 1.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 2.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

4.  Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis.

Authors:  Elham E Amin; Ingrid M Bistervels; Karina Meijer; Lidwine W Tick; Saskia Middeldorp; Guy Mostard; Marlène van de Poel; Erik H Serné; Hans M Otten; Edith M Klappe; Manuela A Joore; Hugo Ten Cate; Marije Ten Wolde; Arina J Ten Cate-Hoek
Journal:  Blood       Date:  2018-09-20       Impact factor: 22.113

Review 5.  Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Authors:  Marc Alan Rodger; Gregoire Le Gal
Journal:  Blood Adv       Date:  2018-11-13

Review 6.  How I use catheter-directed interventional therapy to treat patients with venous thromboembolism.

Authors:  Suresh Vedantham; Akhilesh K Sista
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

Review 7.  Guidance for the treatment of deep vein thrombosis and pulmonary embolism.

Authors:  Michael B Streiff; Giancarlo Agnelli; Jean M Connors; Mark Crowther; Sabine Eichinger; Renato Lopes; Robert D McBane; Stephan Moll; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

8.  Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.

Authors:  Igor A Suchkov; Javier Martinez-Gonzalez; Sebastian M Schellong; Toni Garbade; Michela Falciani
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

9.  Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer.

Authors:  F Dentali; S Barco; S Pegoraro; M N D Di Minno; D Mastroiacovo; F Pomero; C Lodigiani; F Bagna; M Sartori; G Barillari; N Mumoli; M Napolitano; S M Passamonti; R Benedetti; W Ageno; M Di Nisio
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

10.  The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants.

Authors:  Paolo Prandoni; Walter Ageno; Maurizio Ciammaichella; Nicola Mumoli; Nello Zanatta; Davide Imberti; Adriana Visonà; Eugenio Bucherini; Marcello Di Nisio; Franco Noventa
Journal:  Intern Emerg Med       Date:  2019-10-30       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.